{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:21:49Z","timestamp":1760646109081,"version":"3.40.4"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T00:00:00Z","timestamp":1382140800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s11920-013-0415-y","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T01:35:38Z","timestamp":1382060138000},"source":"Crossref","is-referenced-by-count":13,"title":["Pharmacotherapy for Stimulant-Related Disorders"],"prefix":"10.1007","volume":"15","author":[{"given":"Colin N.","family":"Haile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,19]]},"reference":[{"unstructured":"SAMHSA. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. 2013, Substance Abuse and Mental Health Services Administration: Rockville, MD.","key":"415_CR1"},{"issue":"2","key":"415_CR2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pharmthera.2012.01.010","volume":"134","author":"CN Haile","year":"2012","unstructured":"Haile CN et al. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther. 2012;134(2):260\u201377.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"415_CR3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrn3119","volume":"12","author":"RZ Goldstein","year":"2011","unstructured":"Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12(11):652\u201369.","journal-title":"Nat Rev Neurosci"},{"key":"415_CR4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.neuropharm.2012.06.021","volume":"64","author":"M Sofuoglu","year":"2013","unstructured":"Sofuoglu M et al. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013;64:452\u201363.","journal-title":"Neuropharmacology"},{"issue":"7","key":"415_CR5","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/sj.npp.1301263","volume":"32","author":"D Weinshenker","year":"2007","unstructured":"Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology. 2007;32(7):1433\u201351.","journal-title":"Neuropsychopharmacology"},{"doi-asserted-by":"crossref","unstructured":"Patel KT et al. Robust changes in reward circuitry during reward loss in current and former cocaine users during performance of a monetary incentive delay task. Biol Psychiatry. 2013;74(7):529\u201337.","key":"415_CR6","DOI":"10.1016\/j.biopsych.2013.04.029"},{"issue":"1","key":"415_CR7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/syn.20696","volume":"64","author":"YS Ding","year":"2010","unstructured":"Ding YS et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S, S)-[(11)C]O-methylreboxetine and HRRT. Synapse. 2010;64(1):30\u20138.","journal-title":"Synapse"},{"issue":"7","key":"415_CR8","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.157.7.1134","volume":"157","author":"LK Jacobsen","year":"2000","unstructured":"Jacobsen LK et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry. 2000;157(7):1134\u201340.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"415_CR9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pscychresns.2009.05.004","volume":"174","author":"S Yang","year":"2009","unstructured":"Yang S et al. Lower glutamate levels in rostral anterior cingulate of chronic cocaine users - A (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy. Psychiatry Res. 2009;174(3):171\u20136.","journal-title":"Psychiatry Res"},{"issue":"1","key":"415_CR10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/appi.ajp.2011.11010126","volume":"169","author":"R Narendran","year":"2012","unstructured":"Narendran R et al. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry. 2012;169(1):55\u201363.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"415_CR11","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/npp.2008.235","volume":"34","author":"D Martinez","year":"2009","unstructured":"Martinez D et al. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology. 2009;34(7):1774\u201382.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"415_CR12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002130050625","volume":"137","author":"RT Malison","year":"1998","unstructured":"Malison RT et al. [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl). 1998;137(4):321\u20135.","journal-title":"Psychopharmacology (Berl)"},{"doi-asserted-by":"crossref","unstructured":"Payer DE et al. Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [C]-(+)-PHNO. Neuropsychopharmacology. 2013. doi: 10.1038\/npp.2013.192 .","key":"415_CR13","DOI":"10.1038\/npp.2013.192"},{"issue":"6","key":"415_CR14","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1176\/ajp.155.6.832","volume":"155","author":"RT Malison","year":"1998","unstructured":"Malison RT et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry. 1998;155(6):832\u20134.","journal-title":"Am J Psychiatry"},{"issue":"6627","key":"415_CR15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/386830a0","volume":"386","author":"ND Volkow","year":"1997","unstructured":"Volkow ND et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386(6627):830\u20133.","journal-title":"Nature"},{"issue":"4","key":"415_CR16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1176\/appi.ajp.164.4.622","volume":"164","author":"D Martinez","year":"2007","unstructured":"Martinez D et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry. 2007;164(4):622\u20139.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"415_CR17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1176\/appi.ajp.2010.10050748","volume":"168","author":"D Martinez","year":"2011","unstructured":"Martinez D et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry. 2011;168(6):634\u201341.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"415_CR18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1176\/appi.ajp.2009.08121801","volume":"166","author":"D Martinez","year":"2009","unstructured":"Martinez D et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)\/D(3) receptors following acute dopamine depletion. Am J Psychiatry. 2009;166(10):1170\u20137.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"415_CR19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/syn.890140210","volume":"14","author":"ND Volkow","year":"1993","unstructured":"Volkow ND et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse (New York, NY). 1993;14(2):169\u201377.","journal-title":"Synapse (New York, N.Y.)"},{"issue":"4","key":"415_CR20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1176\/appi.neuropsych.16.4.456","volume":"16","author":"K Bolla","year":"2004","unstructured":"Bolla K et al. Prefrontal cortical dysfunction in abstinent cocaine abusers. J Neuropsychiatry Clin Neurosci. 2004;16(4):456\u201364.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"415_CR21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00213-011-2485-z","volume":"219","author":"MJ Fernandez-Serrano","year":"2012","unstructured":"Fernandez-Serrano MJ et al. Neuropsychological profiling of impulsivity and compulsivity in cocaine dependent individuals. Psychopharmacology (Berl). 2012;219(2):673\u201383.","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"415_CR22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/mp.2011.86","volume":"17","author":"GJ Wang","year":"2012","unstructured":"Wang GJ et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry. 2012;17(9):918\u201325.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"415_CR23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.neuron.2011.02.010","volume":"69","author":"D Sulzer","year":"2011","unstructured":"Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron. 2011;69(4):628\u201349.","journal-title":"Neuron"},{"key":"415_CR24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0006-3223(00)01038-6","volume":"49","author":"WC Drevets","year":"2001","unstructured":"Drevets WC et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001;49:81\u201396.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"415_CR25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0090-9556(25)07478-1","volume":"21","author":"CE Cook","year":"1993","unstructured":"Cook CE et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos. 1993;21(4):717\u201323.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"415_CR26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.brainresrev.2009.03.002","volume":"60","author":"IN Krasnova","year":"2009","unstructured":"Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev. 2009;60(2):379\u2013407.","journal-title":"Brain Res Rev"},{"issue":"3","key":"415_CR27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drugalcdep.2012.11.016","volume":"129","author":"WJ Panenka","year":"2013","unstructured":"Panenka WJ et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013;129(3):167\u201379.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"415_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1355617704101021","volume":"10","author":"JD Rippeth","year":"2004","unstructured":"Rippeth JD et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10(1):1\u201314.","journal-title":"J Int Neuropsychol Soc"},{"issue":"3","key":"415_CR29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-006-0330-6","volume":"185","author":"CE Johanson","year":"2006","unstructured":"Johanson CE et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl). 2006;185(3):327\u201338.","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"415_CR30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nm0696-699","volume":"2","author":"JM Wilson","year":"1996","unstructured":"Wilson JM et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2(6):699\u2013703.","journal-title":"Nat Med"},{"issue":"1","key":"415_CR31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archpsyc.63.1.90","volume":"63","author":"Y Sekine","year":"2006","unstructured":"Sekine Y et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63(1):90\u2013100.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"415_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/syn.20471","volume":"62","author":"UD McCann","year":"2008","unstructured":"McCann UD et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse. 2008;62(2):91\u2013100.","journal-title":"Synapse"},{"issue":"6","key":"415_CR33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.mp.4000760","volume":"5","author":"JN Worsley","year":"2000","unstructured":"Worsley JN et al. Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry. 2000;5(6):664\u201372.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"415_CR34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pscychresns.2012.10.003","volume":"211","author":"R Salo","year":"2013","unstructured":"Salo R et al. Behavioral regulation in methamphetamine abusers: an fMRI study. Psychiatry Res. 2013;211(3):234\u20138.","journal-title":"Psychiatry Res"},{"issue":"Pt 2","key":"415_CR35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/brain\/awh046","volume":"127","author":"A Moszczynska","year":"2004","unstructured":"Moszczynska A et al. Why is parkinsonism not a feature of human methamphetamine users? Brain. 2004;127(Pt 2):363\u201370.","journal-title":"Brain"},{"issue":"47","key":"415_CR36","doi-asserted-by":"crossref","first-page":"14734","DOI":"10.1523\/JNEUROSCI.3765-09.2009","volume":"29","author":"B Lee","year":"2009","unstructured":"Lee B et al. Striatal dopamine d2\/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci. 2009;29(47):14734\u201340.","journal-title":"J Neurosci"},{"issue":"4","key":"415_CR37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1523\/JNEUROSCI.4371-11.2012","volume":"32","author":"I Boileau","year":"2012","unstructured":"Boileau I et al. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci. 2012;32(4):1353\u20139.","journal-title":"J Neurosci"},{"issue":"4","key":"415_CR38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/mi.9.4.6","volume":"9","author":"M Gaval-Cruz","year":"2009","unstructured":"Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv. 2009;9(4):175\u201387.","journal-title":"Mol Interv"},{"issue":"1","key":"415_CR39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-3565(25)27684-4","volume":"157","author":"M Goldstein","year":"1967","unstructured":"Goldstein M, Nakajima K. The effect of disulfiram on catecholamine levels in the brain. J Pharmacol Exp Ther. 1967;157(1):96\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"415_CR40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0773.1993.tb01331.x","volume":"72","author":"NL Benowitz","year":"1993","unstructured":"Benowitz NL. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol. 1993;72(1):3\u201312.","journal-title":"Pharmacol Toxicol"},{"issue":"2\u20133","key":"415_CR41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.drugalcdep.2010.07.022","volume":"113","author":"A Oliveto","year":"2011","unstructured":"\u2022 Oliveto A et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 2011;113(2\u20133):184\u201391. A notable outpatient clinical trial that found a low dose of disulfiram increased cocaine use whereas a high dose decreased cocaine use.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"415_CR42","doi-asserted-by":"crossref","first-page":"e47702","DOI":"10.1371\/journal.pone.0047702","volume":"7","author":"CN Haile","year":"2012","unstructured":"\u2022 Haile CN et al. The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. PLoS One. 2012;7(11):e47702. This study was the first to show that low doses of disulfiram increased the cardiovascular and reinforcing effects of cocaine whereas high doses had the opposite effect. These results may help explain outpatient clinical trial data showing low doses of disulfiram increased cocaine use (reference [42\u2022]).","journal-title":"PLoS One"},{"issue":"3","key":"415_CR43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00952990902825447","volume":"35","author":"CN Haile","year":"2009","unstructured":"Haile CN, Kosten TR, Kosten TA. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse. 2009;35(3):161\u201377.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"415_CR44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.biopsych.2012.07.011","volume":"73","author":"TR Kosten","year":"2013","unstructured":"\u2022\u2022 Kosten TR et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry. 2013;73(3):219\u201324. This pharmacogenetic study was the first to show that a polymorphism significantly affected therapeutic response to disulfiram for cocaine use disorder.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"415_CR45","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/npp.2012.68","volume":"37","author":"DA Mitrano","year":"2012","unstructured":"Mitrano DA et al. Alpha-1 Adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. Neuropsychopharmacology. 2012;37(9):2161\u201372.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"415_CR46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/brainsci2040619","volume":"2","author":"CN Haile","year":"2012","unstructured":"Haile CN et al. The \u03b11 antagonist doxazosin alters the behavioral effects of cocaine in rats. Brain Sci. 2012;2(4):619\u201333.","journal-title":"Brain Sci"},{"issue":"10","key":"415_CR47","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.biopsych.2005.02.003","volume":"57","author":"XY Zhang","year":"2005","unstructured":"Zhang XY, Kosten TA. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry. 2005;57(10):1202\u20134.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"415_CR48","doi-asserted-by":"crossref","first-page":"e30854","DOI":"10.1371\/journal.pone.0030854","volume":"7","author":"TF Newton","year":"2012","unstructured":"\u2022\u2022 Newton TF et al. Noradrenergic alpha(1) receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One. 2012;7(2):e30854. In this human laboratory study treatment witih doxazosin blocked the positive subjective effects of cocaine in individuals with cocaine use disorder.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"415_CR49","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.drugalcdep.2012.11.021","volume":"131","author":"D Shorter","year":"2013","unstructured":"\u2022\u2022 Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend. 2013;131(1\u20132):66\u201370. A pilot outpatient clinical trial demonstrating that treatment with doxazosin was associated with decreased cocaine use in treatment-seeking participants with cocaine use disorder.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"415_CR50","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/jpet.108.146142","volume":"329","author":"D Zolkowska","year":"2009","unstructured":"Zolkowska D et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009;329(2):738\u201346.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"415_CR51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2007.03.044","volume":"568","author":"MM Dopheide","year":"2007","unstructured":"Dopheide MM et al. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol. 2007;568(1\u20133):112\u201323.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"415_CR52","doi-asserted-by":"crossref","first-page":"e25790","DOI":"10.1371\/journal.pone.0025790","volume":"6","author":"KC Schmitt","year":"2011","unstructured":"Schmitt KC, Reith MEA. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PloS One. 2011;6(10):e25790.","journal-title":"PloS One"},{"doi-asserted-by":"crossref","unstructured":"Mahler SV, et al. Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. Addict Biol. 2012.","key":"415_CR53","DOI":"10.1111\/j.1369-1600.2012.00506.x"},{"doi-asserted-by":"crossref","unstructured":"Volkow ND et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148\u201354.","key":"415_CR54","DOI":"10.1001\/jama.2009.351"},{"issue":"2","key":"415_CR55","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.addbeh.2012.04.006","volume":"38","author":"AE Goudriaan","year":"2013","unstructured":"Goudriaan AE et al. Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: a randomized placebo-controlled cross-over study using pharmacological fMRI. Addict Behav. 2013;38(2):1509\u201317.","journal-title":"Addict Behav"},{"key":"415_CR56","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.neuropharm.2012.06.064","volume":"64","author":"AD Kalechstein","year":"2013","unstructured":"\u2022 Kalechstein AD et al. Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. Neuropharmacology. 2013;64:472\u20138. In this study, modafinil treatment reversed some cognitive deficits in heavy cocaine users.","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"415_CR57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2009.04.015","volume":"104","author":"AL Anderson","year":"2009","unstructured":"Anderson AL et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009;104(1\u20132):133\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"415_CR58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jsat.2011.12.014","volume":"43","author":"CA Dackis","year":"2012","unstructured":"\u2022 Dackis CA et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat. 2012;43(3):303\u201312. Although modafinil did not decrease use, this study showed gender influences therapeutic response.","journal-title":"J Subst Abuse Treat"},{"key":"415_CR59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fpsyt.2012.00077","volume":"3","author":"JM Schmitz","year":"2012","unstructured":"Schmitz JM et al. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front Psychiatry. 2012;3:77.","journal-title":"Front Psychiatry"},{"issue":"3 Suppl 2","key":"415_CR60","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/JCP.0b013e3181733560","volume":"28","author":"JS Markowitz","year":"2008","unstructured":"Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008;28(3 Suppl 2):S54\u201361.","journal-title":"J Clin Psychopharmacol"},{"doi-asserted-by":"crossref","unstructured":"Konova AB, et al. Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. JAMA Psychiatry 2013;1-11.","key":"415_CR61","DOI":"10.1001\/jamapsychiatry.2013.1129"},{"doi-asserted-by":"crossref","unstructured":"Moeller SJ, et al. Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction. Cereb Cortex. 2012. doi: 10.1093\/cercor\/bhs345 .","key":"415_CR62","DOI":"10.1093\/cercor\/bhs345"},{"doi-asserted-by":"crossref","unstructured":"Volkow ND et al. Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers. PLoS One. 2010;5(7):e11509. doi: 10.1371\/journal.pone.0011509 .","key":"415_CR63","DOI":"10.1371\/journal.pone.0011509"},{"issue":"1","key":"415_CR64","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/npp.2010.145","volume":"36","author":"RZ Goldstein","year":"2011","unstructured":"Goldstein RZ, Volkow ND. Oral methylphenidate normalizes cingulate activity and decreases impulsivity in cocaine addiction during an emotionally salient cognitive task. Neuropsychopharmacology. 2011;36(1):366\u20137.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"415_CR65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2005.09.003","volume":"82","author":"SL Collins","year":"2006","unstructured":"Collins SL et al. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 2006;82(2):158\u201367.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"415_CR66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pbb.2006.06.023","volume":"85","author":"T Winhusen","year":"2006","unstructured":"Winhusen T et al. Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol Biochem Behav. 2006;85(1):29\u201338.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"415_CR67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/JCP.0b013e31827bfff4","volume":"33","author":"KM Dursteler-MacFarland","year":"2013","unstructured":"Dursteler-MacFarland KM et al. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription. J Clin Psychopharmacol. 2013;33(1):104\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20132","key":"415_CR68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2008.10.016","volume":"101","author":"ME Mooney","year":"2009","unstructured":"Mooney ME et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009;101(1\u20132):34\u201341.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"415_CR69","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1037\/1064-1297.10.3.286","volume":"10","author":"H Schubiner","year":"2002","unstructured":"Schubiner H et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10(3):286\u201394.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"415_CR70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0022-3565(25)12810-3","volume":"277","author":"RL Peltier","year":"1996","unstructured":"Peltier RL et al. Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine. J Pharmacol Exp Ther. 1996;277(1):212\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"415_CR71","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00213-003-1409-y","volume":"167","author":"SS Negus","year":"2003","unstructured":"Negus SS, Mello NK. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology (Berl). 2003;167(3):324\u201332.","journal-title":"Psychopharmacology (Berl)"},{"issue":"1\u20133","key":"415_CR72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2008.08.009","volume":"99","author":"CR Rush","year":"2009","unstructured":"Rush CR, Stoops WW, Hays LR. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend. 2009;99(1\u20133):261\u201371.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"415_CR73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/JCP.0b013e3181d21967","volume":"30","author":"CR Rush","year":"2010","unstructured":"Rush CR et al. Cocaine choice in humans during D-amphetamine maintenance. J Clin Psychopharmacol. 2010;30(2):152\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"415_CR74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1749-6632.2009.05145.x","volume":"1187","author":"DV Herin","year":"2010","unstructured":"Herin DV, Rush CR, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann N Y Acad Sci. 2010;1187:76\u2013100.","journal-title":"Ann N Y Acad Sci"},{"doi-asserted-by":"crossref","unstructured":"Haile CN, Garza Ii RDL, Newton TF. Methamphetamine cured my cocaine addiction. J Addict Res Ther. 2010;01(01).","key":"415_CR75","DOI":"10.4172\/2155-6105.1000103"},{"issue":"4","key":"415_CR76","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0269881109103113","volume":"23","author":"DR Jasinski","year":"2009","unstructured":"Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol (Oxford, England). 2009;23(4):419\u201327.","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"11","key":"415_CR77","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.biopsych.2012.05.032","volume":"72","author":"JJ Mariani","year":"2012","unstructured":"\u2022 Mariani JJ et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry. 2012;72(11):950\u20136. Treatment with a combination of mixed amphetamine salts and topiramate achieved greater durations of abstinence from cocaine. The study also found that this combination was most effective for individuals who used more cocaine at baseline.","journal-title":"Biol Psychiatry"},{"issue":"Suppl 1","key":"415_CR78","first-page":"S10","volume":"41","author":"JW Gibbs 3rd","year":"2000","unstructured":"Gibbs 3rd JW et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41 Suppl 1:S10\u20136.","journal-title":"Epilepsia"},{"issue":"3","key":"415_CR79","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1212\/WNL.52.3.473","volume":"52","author":"OA Petroff","year":"1999","unstructured":"Petroff OA et al. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999;52(3):473\u20138.","journal-title":"Neurology"},{"issue":"3","key":"415_CR80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.drugalcdep.2004.03.008","volume":"75","author":"KM Kampman","year":"2004","unstructured":"Kampman KM et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233\u201340.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"415_CR81","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","volume":"168","author":"BA Johnson","year":"2008","unstructured":"Johnson BA et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008;168(11):1188\u201399.","journal-title":"Arch Intern Med"},{"doi-asserted-by":"crossref","unstructured":"\u2022 Kampman KM, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013. Topiramate did not decrease coccaine or alcohol use overall however individuals with more severe cocaine withdrawal symptoms showed a better treatment response.","key":"415_CR82","DOI":"10.1016\/j.drugalcdep.2013.05.026"},{"issue":"3","key":"415_CR83","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1369-1600.2012.00499.x","volume":"18","author":"BA Johnson","year":"2013","unstructured":"Johnson BA et al. Topiramate\u2019s effects on cocaine-induced subjective mood, craving and preference for money over drug taking. Addict Biol. 2013;18(3):405\u201316.","journal-title":"Addict Biol"},{"doi-asserted-by":"crossref","unstructured":"Simmler LD, Wandeler R, Liechti ME. Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Res Notes. 2013;6:220. doi: 10.1186\/1756-0500-6-220 .","key":"415_CR84","DOI":"10.1186\/1756-0500-6-220"},{"issue":"1","key":"415_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0022432","volume":"19","author":"CW Schindler","year":"2011","unstructured":"Schindler CW et al. Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. Exp Clin Psychopharmacol. 2011;19(1):1\u201310.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"3","key":"415_CR86","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00213-005-0102-8","volume":"182","author":"TF Newton","year":"2005","unstructured":"Newton TF et al. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl). 2005;182(3):426\u201335.","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"415_CR87","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.npp.1300979","volume":"31","author":"TF Newton","year":"2006","unstructured":"Newton TF et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006;31(7):1537\u201344.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"415_CR88","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.03.010","volume":"96","author":"S Shoptaw","year":"2008","unstructured":"Shoptaw S et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008;96(3):222\u201332.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"415_CR89","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.npp.1301481","volume":"33","author":"AM Elkashef","year":"2008","unstructured":"Elkashef AM et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008;33(5):1162\u201370.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"415_CR90","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1755-5949.2011.00263.x","volume":"18","author":"DJ McCann","year":"2012","unstructured":"\u2022 McCann DJ, Li SH. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther. 2012;18(5):414\u20138. An imporant reanalysis of data from previous outpatient clinical trials showing bupropion was associated with decreases in methamphetamine use.","journal-title":"CNS Neurosci Ther"},{"issue":"1\u20132","key":"415_CR91","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.drugalcdep.2012.03.027","volume":"125","author":"M Brensilver","year":"2012","unstructured":"Brensilver M et al. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation\/augmentation. Drug Alcohol Depend. 2012;125(1\u20132):169\u201372.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"415_CR92","doi-asserted-by":"crossref","first-page":"943","DOI":"10.15288\/jsad.2011.72.943","volume":"72","author":"AC Dean","year":"2011","unstructured":"Dean AC et al. Acute modafinil effects on attention and inhibitory control in methamphetamine-dependent humans. J Stud Alcohol Drugs. 2011;72(6):943\u201353.","journal-title":"J Stud Alcohol Drugs"},{"issue":"5","key":"415_CR93","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/npp.2010.233","volume":"36","author":"DG Ghahremani","year":"2011","unstructured":"Ghahremani DG et al. Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2011;36(5):950\u20139.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"issue":"9","key":"415_CR94","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1017\/S1461145711001805","volume":"15","author":"JJ Mahoney","year":"2012","unstructured":"Mahoney JJ et al. Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2012;15(9):1241\u20139.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"415_CR95","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/JCP.0b013e3181b591e0","volume":"29","author":"J McGaugh","year":"2009","unstructured":"McGaugh J et al. Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol. 2009;29(5):488\u201391.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"415_CR96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/00952990802342907","volume":"35","author":"MC McElhiney","year":"2009","unstructured":"McElhiney MC et al. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV\u2009+\u2009gay men: a pilot study. Am J Drug Alcohol Abuse. 2009;35(1):34\u20137.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2\u20133","key":"415_CR97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.drugalcdep.2009.08.013","volume":"106","author":"R Garza De La 2nd","year":"2010","unstructured":"De La Garza 2nd R et al. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend. 2010;106(2\u20133):173\u201380.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"415_CR98","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1360-0443.2008.02437.x","volume":"104","author":"J Shearer","year":"2009","unstructured":"Shearer J et al. A double-blind, placebo-controlled trial of modafinil (200 mg\/day) for methamphetamine dependence. Addiction. 2009;104(2):224\u201333.","journal-title":"Addiction"},{"issue":"1\u20133","key":"415_CR99","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drugalcdep.2011.07.007","volume":"120","author":"AL Anderson","year":"2012","unstructured":"Anderson AL et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012;120(1\u20133):135\u201341.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"415_CR100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13556210410001674103","volume":"9","author":"GK Hulse","year":"2004","unstructured":"Hulse GK et al. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol. 2004;9(1):59\u201365.","journal-title":"Addict Biol"},{"issue":"10","key":"415_CR101","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/jnr.22386","volume":"88","author":"X Shen","year":"2010","unstructured":"Shen X et al. mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. J Neurosci Res. 2010;88(10):2294\u2013302.","journal-title":"J Neurosci Res"},{"issue":"6","key":"415_CR102","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11373-006-9102-x","volume":"13","author":"CT Chiu","year":"2006","unstructured":"Chiu CT, Ma T, Ho IK. Methamphetamine-induced behavioral sensitization in mice: alterations in mu-opioid receptor. J Biomed Sci. 2006;13(6):797\u2013811.","journal-title":"J Biomed Sci"},{"issue":"1\u20132","key":"415_CR103","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.brainresbull.2005.05.028","volume":"67","author":"CT Chiu","year":"2005","unstructured":"Chiu CT, Ma T, Ho IK. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull. 2005;67(1\u20132):100\u20139.","journal-title":"Brain Res Bull"},{"issue":"2","key":"415_CR104","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.brainres.2004.06.051","volume":"1021","author":"K Anggadiredja","year":"2004","unstructured":"Anggadiredja K et al. Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res. 2004;1021(2):272\u20136.","journal-title":"Brain Res"},{"doi-asserted-by":"crossref","unstructured":"Jimenez-Gomez C, et al. Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys. Behav Pharmacol. 2010.","key":"415_CR105","DOI":"10.1097\/FBP.0b013e3283423d55"},{"issue":"8","key":"415_CR106","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/sj.npp.1301572","volume":"33","author":"N Jayaram-Lindstrom","year":"2008","unstructured":"Jayaram-Lindstrom N et al. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology. 2008;33(8):1856\u201363.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"415_CR107","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.jcp.0000144893.29987.e5","volume":"24","author":"N Jayaram-Lindstr\u00f6m","year":"2004","unstructured":"Jayaram-Lindstr\u00f6m N et al. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol. 2004;24(6):665\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"415_CR108","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08039480510023052","volume":"59","author":"N Jayaram-Lindstrom","year":"2005","unstructured":"Jayaram-Lindstrom N et al. An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry. 2005;59(3):167\u201371.","journal-title":"Nord J Psychiatry"},{"issue":"11","key":"415_CR109","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1176\/appi.ajp.2008.08020304","volume":"165","author":"N Jayaram-Lindstrom","year":"2008","unstructured":"Jayaram-Lindstrom N et al. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165(11):1442\u20138.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"415_CR110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","volume":"169","author":"J Tiihonen","year":"2012","unstructured":"\u2022 Tiihonen J et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry. 2012;169(5):531\u20136. Implantable naltrexone doubled the percentage of drug-free urines compared to placebo.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"415_CR111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1521-0391.2013.00320.x","volume":"22","author":"E Kelty","year":"2013","unstructured":"Kelty E et al. A retrospective assessment of the use of naltrexone implants for the treatment of problematic amphetamine use. Am J Addict. 2013;22(1):1\u20136.","journal-title":"Am J Addict"},{"issue":"5\u20136","key":"415_CR112","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eurpsy.2005.03.013","volume":"20","author":"X Laqueille","year":"2005","unstructured":"Laqueille X et al. Methylphenidate effective in treating amphetamine abusers with no other psychiatric disorder. Eur Psychiatry. 2005;20(5\u20136):456\u20137.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"415_CR113","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.164.1.160","volume":"164","author":"J Tiihonen","year":"2007","unstructured":"Tiihonen J et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007;164(1):160\u20132.","journal-title":"Am J Psychiatry"},{"doi-asserted-by":"crossref","unstructured":"Miles SW, et al. Extended-release methylphenidate for treatment of amphetamine\/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction 2013.","key":"415_CR114","DOI":"10.1111\/add.12109"},{"issue":"1","key":"415_CR115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/S1461145705006401","volume":"10","author":"BA Johnson","year":"2007","unstructured":"Johnson BA et al. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol. 2007;10(1):85\u201398.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"415_CR116","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.pnpbp.2006.11.011","volume":"31","author":"BA Johnson","year":"2007","unstructured":"Johnson BA et al. Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):455\u201361.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"415_CR117","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pnpbp.2006.08.002","volume":"31","author":"BA Johnson","year":"2007","unstructured":"Johnson BA et al. Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):123\u201330.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"415_CR118","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1360-0443.2011.03771.x","volume":"107","author":"A Elkashef","year":"2012","unstructured":"\u2022 Elkashef A et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107(7):1297\u2013306. Topiramate treatmetn was not associated with reductions in methamphetamine use however relapse rates were reduced in individuals abstinent upon entering the study.","journal-title":"Addiction"},{"issue":"7","key":"415_CR119","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/j.1360-0443.2012.03841.x","volume":"107","author":"F Vocci","year":"2012","unstructured":"Vocci F. Commentary on Elkashef, et al.(2012): just enough efficacy for a second look. Addiction. 2012;107(7):1307\u20138.","journal-title":"Addiction"},{"issue":"6","key":"415_CR120","first-page":"729","volume":"11","author":"R Garza De La","year":"2008","unstructured":"De La Garza R, Shoptaw S, Newton TF. Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. Int J Neuropsychopharmacol. 2008;11(6):729\u201341.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"415_CR121","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pbb.2007.12.010","volume":"89","author":"R Garza De La 2nd","year":"2008","unstructured":"De La Garza 2nd R et al. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav. 2008;89(2):200\u20138.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"415_CR122","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pnpbp.2011.12.014","volume":"37","author":"R Garza De La 2nd","year":"2012","unstructured":"\u2022 De La Garza 2nd R et al. Rivastigmine reduces \u201cLikely to use methamphetamine\u201d in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):141\u20136. This human laboratory study was the first to demonstrate pretreatment with the cognitive enhancer rivastigmine significantly decreases desire for methamphetamine.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"415_CR123","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pbb.2011.05.013","volume":"99","author":"AD Kalechstein","year":"2011","unstructured":"Kalechstein AD et al. Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. Pharmacol Biochem Behav. 2011;99(3):423\u20137.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"415_CR124","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neulet.2008.08.021","volume":"444","author":"TA Jenkins","year":"2008","unstructured":"Jenkins TA. Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats. Neurosci Lett. 2008;444(2):186\u20139.","journal-title":"Neurosci Lett"},{"issue":"1","key":"415_CR125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","volume":"30","author":"KA Reardon","year":"2000","unstructured":"Reardon KA et al. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease. Aust N Z J Med. 2000;30(1):48\u201353.","journal-title":"Aust N Z J Med"},{"issue":"2","key":"415_CR126","doi-asserted-by":"crossref","first-page":"H457","DOI":"10.1152\/ajpheart.00400.2009","volume":"298","author":"M Byku","year":"2010","unstructured":"Byku M, Macarthur H, Westfall TC. Inhibitory effects of angiotensin-(1-7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed. Am J Physiol Heart Circ Physiol. 2010;298(2):H457\u201365.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"415_CR127","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0091-3057(92)90067-P","volume":"41","author":"LA Grupp","year":"1992","unstructured":"Grupp LA. Effects of angiotensin II and an angiotensin converting enzyme inhibitor on alcohol intake in P and NP rats. Pharmacol Biochem Behav. 1992;41(1):105\u20138.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"415_CR128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.psychres.2009.11.011","volume":"179","author":"TF Newton","year":"2010","unstructured":"\u2022 Newton TF, De La Garza 2nd R, Grasing K. The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans. Psychiatry Res. 2010;179(1):96\u2013100. In this human laboratory study pretreatment with the antihypertensive medication perindopril signficantly decreased the subjective effects of methamphetamine.","journal-title":"Psychiatry Res"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-013-0415-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-013-0415-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-013-0415-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T17:27:53Z","timestamp":1746034073000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-013-0415-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,19]]},"references-count":128,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1007\/s11920-013-0415-y","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"type":"print","value":"1523-3812"},{"type":"electronic","value":"1535-1645"}],"subject":[],"published":{"date-parts":[[2013,10,19]]},"article-number":"415"}}